NGL Fine-Chem Ltd Q2 FY26 – The Veterinary Chemist That Filed for the U.S. FDA While Its Profit Went Missing on a Milk Carton
1. At a Glance
If chemistry had a soap opera, NGL Fine-Chem Ltd would be the overachieving nerd who builds a new lab every season but somehow forgets to bring the profit home. With a market cap of ₹825 crore and a current price of ₹1,335, this API manufacturer for the animal health industry just reported Q2 FY26 (September 2025) results that had analysts scratching their heads like a confused cat at a laser pointer.
Revenue jumped to ₹120.26 crore, up a meaty 28.6% YoY, showing that the company is still aggressively chasing growth. But the PAT (Profit After Tax) remained sluggish at ₹9.63 crore, barely moving from ₹9.81 crore in the same quarter last year. The YoY profit dipped -1.83%, as operating margins refused to sit up straight at just 14.27%.
At a P/E of 39.9, EV/EBITDA of 19.3, and ROE of 7.75%, the market seems to be valuing dreams more than cash flows. Meanwhile, promoters hold a steady 72.74%, the dividend yield is a negligible 0.13%, and debt has climbed to ₹88 crore thanks to capex ambitions.
In short – revenue gallops, profit limps, and investors wonder whether NGL Fine-Chem’s next big molecule will cure its own financial headaches.
2. Introduction
Let’s start with a confession – NGL Fine-Chem is the kind of stock that makes accountants and veterinarians equally emotional. Incorporated in 1981, it’s been brewing fine chemicals and APIs for decades, mostly for veterinary use (read: animals get the medicine before shareholders get their returns).
On paper, the company looks like a niche pharmaceutical gem – high entry barriers, WHO-GMP approved facilities, and a decent export footprint across Asia, Europe, and the Americas. But dig deeper, and you’ll find a company that has been investing like a teenager with a new credit card – CAPEX, brownfield, greenfield, new filings, new subsidiaries – the works.
However, the real drama is in its margins. From 31% OPM in FY21, they’ve now crashed to just 9–10%. That’s not erosion; that’s financial acid rain. Yet, the company’s tone in every investor meet is still upbeat – “Phase 1 is commercialized, validation batches underway, regulatory filings in progress, revenue from FY27…” Translation: Revenue aa raha hai, bas thoda wait karo.
The story is both fascinating and frustrating. NGL Fine-Chem knows its chemistry, but when it comes to financial alchemy – turning CAPEX into ROI – it’s still learning the formula.
3. Business Model – WTF Do They Even Do?
At its core, NGL Fine-Chem manufactures and exports pharmaceutical APIs and intermediates – mostly for the veterinary segment (animals), and to a much smaller extent, human APIs. The company’s portfolio boasts ~39 APIs, 4 intermediates, and 12 dosage forms, spread across therapeutic categories like anthelmintics (for worms), antiprotozoals (for parasites), ectoparasiticides (for external pests), and phosphorus supplements.
Think of it as the silent chemical supplier behind the medicines that keep cows, goats, and poultry farms running – the unglamorous yet essential part of the food chain. Around 92% of its revenue comes from animal APIs, while the human and intermediate segments are rounding errors at 4% and 2% each.
The company’s key APIs – Diminazene, Clorsulon, and Buparvaquone – command market shares between 15% and 50% globally, supplying to five of the top ten animal healthcare giants. It’s the pharma world’s version of being the “supplier to the stars” but still living in a rented lab.
Its manufacturing plants are located at Tarapur and Navi Mumbai, holding WHO-GMP, ISO 9001, and cGMP certifications. These plants are constantly being expanded – brownfield here, greenfield there – like the Indian version of “Breaking Bad” but with compliance certificates.
Commentary: Revenue grew handsomely, margins recovered, but PAT barely twitched – a classic “revenues up, profits meh” story. Operating margins improved to 14.27%, but still way below the historical highs of 20–30%. Blame inflation in raw material costs, higher depreciation from new plants, and the company’s love affair with CAPEX.
Annualized EPS stands at roughly ₹62.4, which puts the P/E at ~21x on annualized earnings – slightly saner than the reported trailing P/E of 39.9x, but still pricey
